Drug intelligence / Profile preview

Jiatilai + pembrolizumab

Development stage: Phase 3
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Jiatilai + pembrolizumab is a combination regimen that is not verified in public biomedical databases or clinical trial registries. While pembrolizumab is a well-known humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance anti-tumor immune responses, "Jiatilai" does not correspond to any recognized pharmaceutical active ingredient, development code, or approved brand name. Consequently, the therapeutic efficacy, safety profile, and clinical development status of this specific combination cannot be established.

Targets

C1Q (Complement C1q)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)

Beyond the preview

Go deeper on Jiatilai + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiatilai + pembrolizumab.